united therapeutics corporation is a biotechnology company focused on the development and commercialization of unique products to address the unmet medical needs of patients with chronic and life-threatening conditions. we currently have five approved products on the market, and a long-term mission of providing an unlimited supply of transplantable organs for those who need them! our employees can be found collaborating across the united states, europe and asia. as a group, we are relentless in our pursuit of “medicines for life” and continue to research and develop treatments for cardiovascular and pulmonary diseases, pediatric cancers, and other orphan diseases. #weareunitherians
Company profile
Ticker
UTHR
Exchange
Website
CEO
Martine Rothblatt
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
IVIVA Medical, Inc. • Lung Bioengineering Inc. • Lung Biotechnology PBC, a Delaware public benefit corporation • Miromatrix Medical Inc. • Revivicor, Inc. • United Therapeutics Europe, Ltd., a company incorporated • United Therapeutics Ireland Limited, a company incorporated • Unither Biotech Inc. • Unither Bioelectronics, Inc. • Unither Pharma, LLC ...
IRS number
521984749
UTHR stock data
Latest filings (excl ownership)
8-K
Other Events
27 Feb 24
8-K
United Therapeutics Corporation Reports Fourth Quarter and Full Year 2023 Financial Results
21 Feb 24
10-K
2023 FY
Annual report
21 Feb 24
8-K
Other Events
20 Dec 23
SC TO-T/A
Third party tender offer statement (amended)
13 Dec 23
CORRESP
Correspondence with SEC
13 Dec 23
SC TO-T/A
Third party tender offer statement (amended)
12 Dec 23
SC TO-T/A
Third party tender offer statement (amended)
4 Dec 23
8-K
Other Events
29 Nov 23
SC TO-T
Third party tender offer statement
13 Nov 23
Transcripts
UTHR
Earnings call transcript
2023 Q4
21 Feb 24
UTHR
Earnings call transcript
2023 Q3
1 Nov 23
UTHR
Earnings call transcript
2023 Q2
2 Aug 23
UTHR
Earnings call transcript
2023 Q1
3 May 23
UTHR
Earnings call transcript
2022 Q4
22 Feb 23
UTHR
Earnings call transcript
2022 Q3
2 Nov 22
UTHR
Earnings call transcript
2022 Q2
3 Aug 22
UTHR
Earnings call transcript
2022 Q1
4 May 22
UTHR
Earnings call transcript
2021 Q4
27 Feb 22
UTHR
Earnings call transcript
2021 Q4
24 Feb 22
Latest ownership filings
4
MARTINE A ROTHBLATT
15 Mar 24
4
MARTINE A ROTHBLATT
13 Mar 24
4
Judy D. Olian
13 Mar 24
144
Notice of proposed sale of securities
12 Mar 24
4
Tommy G Thompson
12 Mar 24
4
Katherine J Klein
11 Mar 24
4
MARTINE A ROTHBLATT
11 Mar 24
4
Tommy G Thompson
11 Mar 24
4
PAUL A MAHON
7 Mar 24
4
Richard Giltner
7 Mar 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Institutional ownership, Q3 2023
96.8% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 501 |
Opened positions | 76 |
Closed positions | 38 |
Increased positions | 163 |
Reduced positions | 176 |
13F shares | Current |
---|---|
Total value | 9.73 tn |
Total shares | 45.55 mm |
Total puts | 144.80 k |
Total calls | 101.60 k |
Total put/call ratio | 1.4 |
Largest owners | Shares | Value |
---|---|---|
BLK Blackrock | 5.11 mm | $1.15 tn |
Vanguard | 4.66 mm | $1.05 tn |
Wellington Management | 4.12 mm | $930.99 bn |
Avoro Capital Advisors | 2.85 mm | $644.29 bn |
FMR | 2.60 mm | $588.34 bn |
Renaissance Technologies | 2.25 mm | $508.45 bn |
Integrated Core Strategies | 2.24 mm | $175.63 mm |
STT State Street | 1.88 mm | $424.47 bn |
JHG Janus Henderson | 876.57 k | $197.98 bn |
Geode Capital Management | 830.25 k | $187.32 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
14 Mar 24 | Rothblatt Martine A | Common Stock | Sell | Dispose S | No | Yes | 241.4109 | 158 | 38.14 k | 130 |
14 Mar 24 | Rothblatt Martine A | Common Stock | Sell | Dispose S | No | Yes | 240.4726 | 1,267 | 304.68 k | 288 |
14 Mar 24 | Rothblatt Martine A | Common Stock | Sell | Dispose S | No | Yes | 238.493 | 3,098 | 738.85 k | 1,555 |
14 Mar 24 | Rothblatt Martine A | Common Stock | Sell | Dispose S | No | Yes | 237.6187 | 5,955 | 1.42 mm | 4,653 |
14 Mar 24 | Rothblatt Martine A | Common Stock | Sell | Dispose S | No | Yes | 236.7428 | 4,522 | 1.07 mm | 10,608 |
14 Mar 24 | Rothblatt Martine A | Common Stock | Option exercise | Acquire M | No | Yes | 129.49 | 15,000 | 1.94 mm | 15,130 |
14 Mar 24 | Rothblatt Martine A | Stock Options Common Stock | Option exercise | Dispose M | No | Yes | 129.49 | 15,000 | 1.94 mm | 596,654 |
13 Mar 24 | Rothblatt Martine A | Common Stock | Sell | Dispose S | No | Yes | 248.4198 | 205 | 50.93 k | 130 |
13 Mar 24 | Rothblatt Martine A | Common Stock | Sell | Dispose S | No | Yes | 247.1873 | 351 | 86.76 k | 335 |
13 Mar 24 | Rothblatt Martine A | Common Stock | Sell | Dispose S | No | Yes | 246.1676 | 1,195 | 294.17 k | 686 |
News
United Therapeutics Filed Motion In U.S. District Court For The District Of Delaware For Preliminary Injunction In Its Patent Litigation With Liquidia Technologies' Efforts To Seek FDA Approval For PH-ILD For Its Inhaled Treprostinil Product-8K
27 Feb 24
Beyond The Numbers: 4 Analysts Discuss United Therapeutics Stock
22 Feb 24
Wedbush Reiterates Outperform on United Therapeutics, Maintains $308 Price Target
22 Feb 24
HC Wainwright & Co. Reiterates Buy on United Therapeutics, Maintains $300 Price Target
22 Feb 24
United Therapeutics' Challenges FDA Over Liquidia's Drug Approval Process, Clocks Strong Q4 Earnings
21 Feb 24
Press releases
United Therapeutics Corporation to Present at the Leerink Partners Global Biopharma Conference 2024
5 Mar 24
United Therapeutics Corporation Reports Fourth Quarter and Full Year 2023 Financial Results
21 Feb 24
United Therapeutics Commences Litigation to Ensure Fairness in the Drug Review Process
21 Feb 24
United Therapeutics Corporation to Report Fourth Quarter and Full Year 2023 Financial Results Before the Market Opens on Wednesday, February 21, 2024
14 Feb 24
United Therapeutics Corporation to Present at the 42nd Annual J.P. Morgan Healthcare Conference
29 Dec 23